Expertise in
1
conditions

Carine Chaleteix

Clermont-ferrand, FR 
Expertise in
1
conditions
Clermont-ferrand, FR 

Overview

Carine Chaleteix practices practicing medicine in Clermont-ferrand, France.

Ms. Chaleteix is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Multiple Myeloma, Peripheral Neuropathy, Leukemia, Venous Thromboembolism (VTE), and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Clermont-ferrand, France
Other Locations
Limoges, France
Rennes, France
Nantes, France
Amiens, France
Reims, France
Nancy, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Enrollment Status: Completed
Publish Date: November 24, 2025
Intervention Type: Procedure, Drug
Study Drug: Pomalidomide+Cyclophosphamide+Dexamethasone
Study Phase: Phase 2
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Lenalidomide and GA101
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

21 Total Publications

Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.
Journal: The New England journal of medicine
Published: June 03, 2025

Frequently Asked Questions about Carine Chaleteix

Is Carine Chaleteix a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Carine Chaleteix is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Carine Chaleteix participate in research or clinical trials?

Yes. Carine Chaleteix has published 21 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Carine Chaleteix's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Chaleteix's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile